avelumab

January 25, 2019

Phase 3 Trial of Bavencio in Ovarian Cancer is Terminated

News

The immune checkpoint inhibitor Bavencio (avelumab) — given in combination and/or after platinum-based chemotherapy — is no better than chemotherapy alone at delaying disease progression or death in previously untreated women with ... Read more

August 10, 2018

Collaboration Tests TRX518-Bavencio Combo in Phase 1/2 Trial of Solid Tumors

News

Leap Therapeutics is launching a Phase 1/2 clinical trial to test its immunotherapy TRX518 in combination with Bavencio (avelumab) and chemotherapy in advanced solid tumors, as part of a collaboration established with Merck KGaA and Pfizer — the two ... Read more

January 19, 2018January 19, 2018

Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer

News

A new Phase 1b clinical trial testing a combination treatment of Hu5F9-G4 with avelumab in patients with ovarian cancer is set to begin as part of an agreement between Forty Seven and Merck KGaA, Darmstadt, ... Read more

February 1, 2017February 1, 2017

Clinical Study of Combo, Avelumab and Defactinib, in Advanced Ovarian Cancer Begins

News

A Phase 1/2 clinical trial evaluating the investigational drugs avelumab, a PD-L1 inhibitor, and defactinib, a FAK inhibitor, in patients with advanced ovarian cancer has dosed its first patient, Verastem announced. The ... Read more